We proposed to determine, in a real-world clinical setting, the rate of TBI reactivation in psoriatic patients with previously or newly diagnosed LTBI, treated with risankizumab over a follow-up period of 52 weeks, comparing those who had undergone TB chemoprophylaxis with those who had not.

Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world study

Raimondo, A
Writing – Original Draft Preparation
;
Lembo, S
Methodology
2024-01-01

Abstract

We proposed to determine, in a real-world clinical setting, the rate of TBI reactivation in psoriatic patients with previously or newly diagnosed LTBI, treated with risankizumab over a follow-up period of 52 weeks, comparing those who had undergone TB chemoprophylaxis with those who had not.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11386/4897215
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact